Gene Editing Editas Boosts IPO Target Despite Wall Street Gloom
This article was originally published in Scrip
CRISPR-based therapy developer Editas Medicine Inc. has increased its fundraising target in a forthcoming initial public offering to as much as $122m from an initial $100m goal, a move that looks set to test current negative sentiment on sagging stock markets.
You may also be interested in...
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.